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Background: MicroRNAs (miRNAs) are short non-coding RNA molecules that play a critical role in mRNA cleavage
and translational repression, and are known to be altered in many diseases including breast cancer. MicroRNA-10a
(miR-10a) has been shown to be deregulated in various cancer types. The aim of this study was to investigate miR-10a
expression in breast cancer and to further delineate the role of retinoids and thyroxine in regulation of miR-10a.
Methods: Following informed patient consent and ethical approval, tissue samples were obtained during surgery.
miR-10a was quantified in malignant (n = 103), normal (n = 30) and fibroadenoma (n = 35) tissues by RQ-PCR. Gene
expression of Retinoic Acid Receptor beta (RARβ) and Thyroid Hormone receptor alpha (THRα) was also quantified in the
same patient samples (n = 168). The in vitro effects of all-trans Retinoic acid (ATRA) and L-Thyroxine (T4) both individually
and in combination, on miR-10a expression was investigated in breast cancer cell lines, T47D and SK-BR-3.
Results: The level of miR-10a expression was significantly decreased in tissues harvested from breast cancer patients
(Mean (SEM) 2.1(0.07)) Log10 Relative Quantity (RQ)) compared to both normal (3.0(0.16) Log10 RQ, p < 0.001) and benign
tissues (2.6(0.17) Log10 RQ, p < 0.05). The levels of both RARβ and THRα gene expression were also found to be decreased
in breast cancer patients compared to controls (p < 0.001). A significant positive correlation was determined between
miR-10a and RARβ (r = 0.31, p < 0.001) and also with THRα (r = 0.32, p < 0.001). In vitro stimulation assays revealed miR-10a
expression was increased in both T47D and SK-BR-3 cells following addition of ATRA (2 fold (0.7)). While T4 alone did not
stimulate miR-10a expression, the combination of T4 and ATRA was found to have a positive synergistic effect.
Conclusion: The data presented supports a potential tumour suppressor role for miR-10a in breast cancer, and highlights
retinoic acid as a positive regulator of the microRNA.
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(RARβ)Background
MicroRNAs (miRNAs) are an important class of short
non-coding RNA molecules proven to have a critical
role in mRNA cleavage or decay [1]. miRNAs play
crucial roles in a variety of physiological as well as
pathological processes including breast cancer [2]. They
have been shown to be dysregulated in both tissue
and circulation of cancer patients [3-7].
miR-10a is located on chromosome 17q21.32 and is a
member of the HOX gene cluster (HOXB and HOXD)
[8]. In the miR-10 family, particularly miR-10a/b display
relevant roles in developmental pathways which also* Correspondence: roisin.dwyer@nuigalway.ie
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unless otherwise stated.feature in cancer-related processes [9]. Deregulation of
miR-10a has been reported in a number of cancers,
including gastric, cervical and thyroid cancer [10-12].
Loss of miR-10a expression was reported in gastric cancer
tissues, and in cell lines. This report highlighted a potential
tumour suppressor role for miR-10a, partly mediated
through DNA methylation [10]. Elevated expression on the
other hand was observed in primary cervical tumours. This
was associated with an increased risk of developing
metastasis facilitated by its binding to phosphatase
tensin homologue (PTEN) [11]. Inhibition of both
miR-10a and miR-10b was found to promote metastasis in
neuroblastoma cell lines [13,14].
In the context of breast cancer, miR-10a expression has
been shown to display both oncomiR as well as tumourhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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estrogen receptor (ER)-positive tumours was associated
with a longer relapse-free time following Tamoxifen
treatment [15]. A study by Chang et al. [16] reported
a trend towards increased expression of miR-10a in
breast tumours compared to matched tumour associated
normal tissues. This study implicated both miR-10a/b
expression to be associated with adverse outcomes for
breast cancer patients. A study by Pogribny et al. [18] also
showed higher expression of miR-10a in breast cancer
MCF-7 cell lines with an inbuilt resistance to cisplatin.
This analysis identified a potential role for miR-10a in the
regulation of cellular proteins, including homeobox family
HOXD10, tumour suppressor p27 and ER-alpha (ERα)
[18]. Loss of miR-10a expression has been reported by
Peres-Riva et al. [17]. A microarray analysis was per-
formed on primary breast tumours from patients with
early and late recurrence of the disease. The level of
miR-10a was significantly reduced in patients with
early breast cancer recurrence, potentially predicting
patients at risk of developing recurrence of the disease. A
global miRNA profiling study revealed miR-10a to be
involved in inhibition of HOXD4 expression in breast
cancer cell lines [8].
All-trans-retinoic acid (RA) is a known anti-cancer
agent, implicated in a variety of cancers, including lung,
head and neck, and haematological malignancies [19-21].
This has been shown through its anti-proliferative,
pro-apoptotic and anti-oxidative effects in cell line
and animal models [22]. One of the key regulatory
targets of RA is retinoic acid receptor beta (RARβ)
[23]. It has been revealed to inhibit breast cancer cell
proliferation in vitro [24,25], and has also been shown
to inhibit mammary carcinogenesis in mice [26]. This
group and others have reported reduced expression in
tumours [27-30]. This protein also has been shown to
have a potential tumour suppressor role in breast
cancer and is known to dimerize with Thyroid hormone
receptor alpha (THRα) [27,31-33].
Studies have reported a link between miR-10a and RA
[13,14,34]. In T cells, stimulation with RA alone, or com-
bined with transforming growth factor beta (TGF-β) has
been shown to induce miR-10a expression [34]. This
type of stimulation by RA has also been reported in a
pancreatic and a neuroblastoma cell line model as well as
during smooth muscle differentiation [14,35,36]. Based on
the conflicting studies to date, the aim of this study
was to establish the baseline expression of miR-10a in
breast cancer and any potential relationship with RA
and L-Thyroxine.
Expression of miR-10a was quantified in tissues from
breast cancer patients (n = 103), healthy controls (n = 30)
and patients with benign breast disease (n = 35). Any rela-
tionship with clinicopathological details was investigated.RARβ and THRα gene expression were previously
quantified in the same cohort and any association
with miR-10a expression was examined. The impact




All experimental procedures involving tissue samples
from human participants were approved by the Clinical
Research Ethics Committee (University College Hospital,
Galway). Written informed consent was obtained from
each patient and all clinical investigation was performed
according to the principles expressed in the Declaration
of Helsinki.
Clinical samples
Breast tissue specimens (n = 168) were obtained at
University College Hospital, Galway. The clinical patient
samples comprised of 103 malignant tissue biopsies, 30
normal mammary tissue biopsies obtained at reduction
mammoplasty, and 35 fibroadenoma tissues which are
benign breast disease tissues. Full patient demographics
and clinicopathological details were collected and main-
tained prospectively (Table 1). Samples were immersed in
RNAlater® (Qiagen) for 24 hours, then the RNAlater® was
removed and the tissue stored at −80°C until required.
Cell lines and culture conditions
T47D and SK-BR-3 breast cancer cell lines were previously
purchased from the American Type Culture Collection
(Manassas, VA). T47D cells were cultured in RPMI-1640
media and SK-BR-3 cells were cultured in McCoy’s 5A.
Both media types were supplemented with 10% fetal bovine
serum (FBS) and 100U/ml penicillin/ 100 μg streptomycin
(P/S). Cells were incubated at 37°C and 5% CO2 with a
media change performed twice weekly and passage every
7 days.
Total and micro RNA extraction
Breast tissue specimens or cell pellets were homogenised
in 1 ml TRIzol® lysis reagent (Invitrogen) as previously
described [27]. Total (large and micro) RNA was
extracted from malignant (n = 103), normal (n = 30) and
fibroadenoma (n = 35) mammary tissue using the RNeasy
Mini Kit (QIAGEN) as per manufacturer’s instructions.
Gene and microRNA analysis
1 μg of large RNA was reverse transcribed using
SuperScript III reverse transcriptase enzyme (200U/μl),
0.1 M DTT, RT-5x Buffer, RNaseOut Ribonulease Inhibitor
(40U/μl), Random primers (3 μg/μl) and dNTP’s (100 mM)-
Promega (Invitrogen, Carlsbad, CA, USA). TaqMan® Gene
Expression Assays targeting RARβ and THRα (Table 2)
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RARß 3p24.2 Forward: CTCCCTCCCTGCCTAACCA
Reverse: TCCACTGCCTCTTAGCATTTACT
THRα 17q11.2 Forward: TGACCATCGCCGTTAT
Reverse: GCTTTTGTTGGCGTAC
hsa-miR-10a 17q21.32 Forward: GGAGGGGTACCAGAATCCCATTTTGGCCA
Reverse: GGAGGAAGCTTGCGGAGTGTTTATGTCAACT
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Biosystems). 100 ng of mature miR-10a (Table 2) was
reverse transcribed using the MultiScribe™-based
High-Capacity cDNA Archive Kit (dNTP 100 mM,
RT Buffer 10x, RNase Inhibitor 20U/μl, Stem loop primer
50nM, MultiScribe RT 50U/μl) (Appied Biosystems). The
resulting cDNA for both mRNA and microRNA was
analysed using the ABI 79000 Fast real-time PCR system
(Applied Biosystems). These reactions were carried out in
a final volume of 10 μl comprising of 0.7 μl cDNA, 5 μl
TaqMan® Universal PCR fast Master Mix (2×), 0.5 μl
TaqMan® primer-probe mix (0.2 μM), Forward primer
(1.5 μM), and Reverse Primer (0.7 μM) (Applied Biosystems).
The RQ-PCR cycle comprised of 10-minute incubation at95°C followed by a 40 cycles at 95°C for 15 seconds and
60°C for 60 seconds. The use of an Inter-assay control
derived from a breast cancer cell line (T47D) on each
reaction allowed comparison of data across plates, and all
reactions were carried out in triplicate with a standard
deviation of < 0.3 between replicates considered accept-
able. The relative quantity of mRNA and miRNA expres-
sion was calculated using the comparative cycle threshold
(ΔΔCt) [37]. The endogenous controls used for gene
expression were Mitochondrial Ribosomal Protein L19
(MRPL19) and Peptidyl-Prolyl Isomerase A (PPIA) [38].
For the miRNA analysis, let-7a was employed as an
endogenous control [39]. The geometric mean of the
Ct value was used to normalise the data and the sam-
ple with the lowest expression level was applied as a
calibrator.
In vitro stimulation of breast cancer cell lines with
all-trans retinoic acid (ATRA) and L-thyroxine (T4)
T47D and SK-BR-3 cell lines were seeded at 2.4×104
cells/cm2 in a 6-well plate. The following day, the cells
were exposed to all-trans Retinoic Acid (ATRA, 0.1 μM,
1 μM, 5 μM) or L-Thyroxine (T4, 0.1 μM, 0.5 μM, 5 μM)
for 24 hours. This was carried out to establish optimal
concentrations for the assay [27]. Once optimal concen-
trations were established (ATRA, 1 μM, 5 μM and T4
0.5 μM), the assay was then performed in triplicate in both
cell lines. The cells were also exposed to a combination of
ATRA (1 μM or 5 μM) and T4 (0.5 μM) for 24 hours.
Controls included cells cultured in the appropriate
diluents used for each stimulant. Dimethyl sulphoxide
(DMSO, 0.5%) for was used to dilute ATRA. Ammonium
hydroxide (NH4OH, 0.1%) was the appropriate diluent for
T4. Cells were harvested at the appropriate time point by
trypsination, centrifuged at 120 × g for 4 mins and the cell
pellet stored at −80°C. Total large and microRNA was
extracted, and the corresponding cDNA analysed using
RQ-PCR targeting miR-10a, RARβ and THRα. The
endogenous controls used were let-7a for miRNA
analysis, and MPRL19 and PPIA for gene expression
analysis as previously described. The data was expressed
relative to cells cultured in appropriate diluent controls.
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All data are presented as Mean (SEM), and graphically
represented using box plots and linear scatter plots.
A general ANOVA model was used to compare mean
responses. Scatter plots were displayed using Linear
Regression and Lowess smoother to determine the
relationships between different populations. The level of
relationship was determined using Pearson correlation
coefficients.
Results
miR-10a expression in human breast tissues
MicroRNA extracted from malignant (n = 103), normal
(n = 30) and fibroadenoma (n = 35) breast tissue biopsies
(Table 1) was analysed by RQ-PCR. Levels of miR-10a
were significantly decreased in breast cancer tissues
(n = 103, 2.3(0.08) Log10 RQ) compared to both normal
(n = 30, 3.1(0.17) Log10 RQ, p < 0.001) and fibroadenoma
tissues (n = 35, 2.9(0.15) Log10 RQ, p < 0.001, Figure 1).
miR-10a expression was further stratified based on patient
clinicopathological details. Expression of miR-10a was not
dysregulated across epithelial subtype (p = 0.168), tumour
grade (p = 0.299), tumour stage (p = 0.340) or menopausal
status (p = 0.126, results not shown).
RARβ and THRα gene expression in human breast tissues
Expression levels of RARβ and THRα were previously
reported by this group, on a total of n = 100 breast
tissues, consisting of n = 75 breast cancers, n = 10
fibroadenoma tissues and n = 15 normal breast tissues
[27]. Supplementary data shows results from increasing
patient sample number to include a total of n = 168 breast
tissues for the analysis. This RNA was extracted from an
additional n = 27 breast tumours, n = 20 fibroadenoma
and n = 15 normal breast tissues was quantified byFigure 1 MicroRNA-10a (miR-10a) expression in normal, fibroadenoma
and malignant breast tissues. RQ-PCR of miR-10a revealed significantly
decreased levels of expression in breast cancer n = 103 (Mean(SEM)
2.3(0.08)Log10 Relative Quantity (RQ)) compared to normal tissue
n = 30 (3.1(0.17) Log10 RQ, p < 0.001) and fibroadenoma tissues
(n = 35, 2.9(0.15) Log10 RQ, p < 0.001).RQ-PCR targeting RARβ and THRα. RARβ gene expres-
sion was found to be significantly down-regulated in breast
cancer (n = 101, 0.83 (0.04) Log10 RQ) compared to both
normal (n = 27, 1.35 (0.09) Log10 RQ, p < 0.001) and fibro-
adenoma tissue (n = 32, 1.49 (0.07) Log10 RQ, p < 0.001,
Additional file 1: Figure S1.). No significant association was
observed with epithelial subtype (p = 0.122), tumour grade
(p = 0.363), tumour stage (p = 0.614) or menopausal status
(p = 0.635, results not shown).
Levels of THRα were found to be significantly decreased
in breast cancer (n = 101, 0.90 (0.03) Log10 RQ) compared
to both normal (n = 27, 1.50 (0.06) Log10 RQ, p < 0.001)
and fibroadenoma tissues (n = 32, 1.28(0.07), p < 0.001,
Additional file 2: Figure S2.). Further analysis revealed
THRα expression was not significantly deregulated across
epithelial subtype (p = 0.116), tumour stage (p = 0.859) or
menopausal status (p = 0.679, results not shown).
Expression of miR-10a across 168 breast tissues
was correlated with the gene expression results for
RARβ and THRα. A significant positive correlation with
RARβ gene expression was observed (r = 0.31, p < 0.001,
Figure 2A). miR-10a expression also revealed a robust
positive correlation with THRα gene expression (r = 0.32,
p < 0.001, Figure 2B).
In vitro stimulation of breast cancer cells with ATRA or T4
alone or in combination
This study was performed to determine the impact of
all-trans retinoic acid (RA) and L-Thyroxine (T4) on
miR-10a expression in vitro. The following concentra-
tions were selected for the analysis, ATRA (1 μM and
5 μM) and T4 (0.5 μM). This was determined based on
preliminary studies, and reflected the most effective
doses. Cells were harvested, and changes in miR-10a
expression were quantified by RQ-PCR.
In the case of the T47D cells, miR-10a expression was
shown to be stimulated at 1 μM ATRA (2.2 fold,
SEM(0.6), p = 0.11) and 5 μM ATRA (2.3 fold, SEM(0.7),
p = 0.2). In the presence of 0.5 μM T4, no stimulation of
miR-10a expression was observed (0.64 fold, (0.08),
p < 0.05). When combining both reagents, a significant
synergistic increase was shown at 1 μM ATRA+ 0.5 μM T4
(3.1 fold, (0.3), p < 0.005) and at 5 μM ATRA+ 0.5 μM T4
(3.4 fold, (0.8), p < 0.05).
In the SK-BR-3 cells, ATRA alone had a significant
impact on miR-10a expression (3.5-4.1 fold (1.2) p < 0.005,
Figure 3B). Similar to the T47D cells, SK-BR-3 cells did
not show a change in miR-10a expression following stimu-
lation with T4 alone (0.7 fold (0.5)). Combining ATRA and
T4 resulted in a synergistic impact on miR-10a expression
(2.5-2.6 fold (0.2), p < 0.005).
The impact of ATRA or T4 on receptors was also
determined. In the T47D cells, RARβ gene expression
was increased by 99–183 fold following stimulation
Figure 2 Pearson Correlation of miR-10a and Retinoic Acid Receptor Beta (RARβ) and Thyroid hormone receptor alpha (THRα). (A) Pearson
correlation of miR-10a and RARβ revealed a significant positive correlation (r = 0.31, p < 0.001). (B) The same positive correlation was observed
between miR-10a and THRα (r = 0.32, p < 0.001).
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gated this effect (76–92 fold increase). Stimulation with T4
alone or in combination had no impact on expression of
THRα (0.8-1.5 fold, Figure 4B). In the SK-BR-3 cells,
combination of ATRA and T4 stimulated increased RARβ
expression (37–48 fold increase, Figure 4C), with no
change observed in THRα (Figure 4D) or RARβ in any
other conditions.
Discussion
Currently there are varied reports on expression of
miR-10a in breast cancer. Most recently, a study by
Chang et al. [16] quantified miR-10a levels in 108
breast tissues compared to matched tumour associatednormal (TAN) tissues, and found no significant changes
in malignancy. In contrast, the present study quantified
the expression of miR-10a in a total of 168 breast tissues
by RQ-PCR. Expression of miR-10a was found to be
significantly reduced in breast cancer tissues (n = 103)
compared to normal (n = 30) and benign breast disease
tissues (n = 35). The different results observed between
both studies might be as a consequence of the type of
control tissue employed. The present study included
control tissues from patients with no history of the disease
as well as patients with benign breast disease, while the
previous study looked at expression levels in tissue from
the tumour-bearing breast of the same patients. The data
reported here is also supported by another study, showing
Figure 3 miR-10a Expression in breast cancer cell lines following stimulation with All-trans Retinoic Acid (ATRA) or L-Thyroxine (T4) alone or in
combination. (A) miR-10a expression was quantified by RQ-PCR in T47D cells following 24 hours stimulation with ATRA (1 μM and 5 μM) and T4
(0.5 μM) alone or in combination and (B) in SK-BR-3 cells.
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embedded (FFPE) breast tumour tissues from patients
with early recurrence of the disease [17]. This study by
Peres-Riva et al. [17] included a microRNA array on
FFPE tissues, and determined that loss of miR-10a
was associated with the likelihood of developing
metastasis. Reduced expression of miR-10a was also
previously observed in other types of cancers including
gastric cancer and intestinal neoplasia [10,40]. No associa-
tions with patient clinicopathological details were observed
in the current study.
RARβ is a known tumour suppressor in breast cancer
[24,27], confirmed in both cell line and animal models.
In the present study, RARβ gene expression was signifi-
cantly reduced in breast cancer tissues compared to
healthy controls. THRα, which is known to dimerizewith RARβ [32,33], has also previously been implicated
to have a potential tumour suppressor role in breast
cancer tissues, confirmed using western blot analysis
[27,31]. In the present study, reduced expression was
reported in breast cancer tissues compared to healthy
controls. A significant positive correlation was observed
between miR-10a and RARβ and with THRα in breast
tissues. This observation supports a tumour-suppressor
role for miR-10a, and instigated further analysis into the
potential regulation of miR-10a through RA. Previously
miR-10a expression has been shown to be regulated
by RA [35], where elevated miR-10a expression in a
pancreatic cancer cell line model was reduced using
RA inhibitors. In another study, RA elevated miR-10a
expression in T helper cells in vitro, resulting in enhanced
plasticity of these helper cells [34].
Figure 4 Retinoic acid receptor beta (RARβ) and Thyroid hormone receptor alpha (THRα) gene expression following In Vitro Stimulation in breast
cancer cell lines with ATRA or T4 alone or in combination. (A) RARβ gene expression in T47D cells (B) THRα gene expression in T47D cells (C) RARβ
gene expression in SK-BR-3 cells (D) THRα gene expression in SK-BR-3 cells.
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In the present study miR-10a expression was not
affected by stimulation of T47D cells with ATRA or T4
alone. Treatment with a combination of ATRA and T4 on
the other hand showed a greater than 2 fold change in
miR-10a expression. In the Her2 amplified SK-BR-3
cell lines however, ATRA alone showed a 2 fold
change increase in miR-10a expression compared to
the ER positive T47D cells.
Retinoids are used as chemopreventive and anticancer
agents because of their ability to regulate cell differenti-
ation, growth and proliferation and apoptosis [22]. This
data presented supports a potential tumour suppressor
role for miR-10a in breast cancer, and highlights RA
alone or in combination with T4 as a positive regulator
of the miRNA.Additional files
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